A study of CTI-1601 for the treatment of Friedreich's Ataxia.
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2017
At a glance
- Drugs CTI 1601 (Primary)
- Indications Friedreich's ataxia
- Focus Adverse reactions
- 14 Feb 2017 New trial record
- 06 Feb 2017 According to a Chondrial Therapeutics media release, company is planning to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) and after acceptance of the IND, company will initiate this trial.